LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.

Also called NCT04728932

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 206 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04728932
  • EudraCT 2019-004319-29
Other papers using this trial's data
  • Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock: The LEVOECMO Randomized Clinical Trial JAMA, 2026-01-06 DOI, PubMed 41324946, PMC12670262 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04728932. Randomized; triple masking; primary purpose treatment. Start 2021-08-27 (actual); primary completion 2024-11-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients
Acronym
LEVOECMO
Condition
Cardiogenic Shock
Condition
Extracorporeal Membrane Oxygenation Complication
Intervention (Drug)
Levosimendan
Intervention (Drug)
Placebo of Levosimendan
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)

Record details

Record id
cardio:ct-nct04728932
Content hash
fc38b738caea6e060145e41c74de147b735ba4e4270c8d477a275ccb42432c0e